Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 12/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292549 | 0.92 | GRM4 (0.48) | GRM4KDRKCNK3KCNK9NPC1 | |
| SCHEMBL2298619 | 0.91 | RAB9A (0.52) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2294478 | 0.89 | NPC1 (0.48) | GRM4KCNK3KCNK9NPC1RAB9A | |
| SCHEMBL5300582 | 0.88 | TP53 (0.45) | GRM4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2295384 | 0.87 | KCNK3 (0.46) | KCNK3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2299761 | 0.86 | SMN1; SMN2 (0.49) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL2297630 | 0.86 | SMN1; SMN2 (0.51) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL2297443 | 0.86 | CBLB (0.47) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2292264 | 0.85 | NPC1 (0.44) | KDRNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2299394 | 0.85 | F2 (0.44) | NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | GRM4 2364/4885KDR 455/4885KCNK3 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.